Therapeutic effects and anti-metastasis effects of cationic liposomes against pancreatic cancer metastasis in vitro and in vivo

Ichihara, Hideaki; Motomura, Muneaki; Matsumoto, Yōko

doi:10.1016/j.bbrc.2019.02.116

Cited by 8 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The nanocarriers are demonstrated to enhance the therapeutic efficacy, reduce the unwanted adverse effects, improve the blood circulation, and improve the cellular accumulation in the tumor tissues (Lockhart et al 2015;Ramasamy et al 2017). To be specific, liposome has emerged as one of the most tested carrier system in clinical trials (Ichihara et al 2019). The unique structure of liposome provides high drug loading, surface modifications, plasma stability and tunable particle size.…”

Section: Introductionmentioning

confidence: 99%

CD59 receptor targeted delivery of miRNA-1284 and cisplatin-loaded liposomes for effective therapeutic efficacy against cervical cancer cells

Wang

Liang

2020

AMB Expr

View full text Add to dashboard Cite

Co-delivery of two different therapeutics (miRNA-1284 and cisplatin (CDDP)) into the cancer cells in a single nanocarrier provides new dimension to the cancer treatment. In this study, we have designed the CD59sp-conjugated miRNA-1284/cisplatin(CDDP)-loaded liposomes for the enhanced therapeutic effect against cervical cancers. Compared with miRNA-1284/CDDP-loaded liposomes (LP-miCDDP), CD59 antibody-conjugated LP-miCDDP (CD/LP-miCDDP) showed a significantly higher cytotoxicity in HeLa cells. Notably, MiR-1284 showed a typical concentrationdependent cell killing effect in the cervical cancer cells owing to the downregulation of HMGB1. Flow cytometer analysis showed that CD/LP-miCDDP resulted in maximum apoptosis effect (~ 60%) compared to CDDP (~ 20%) or miR-1284 (~ 12%) treated cells indicating the superior anticancer effect in the cancer cells. Importantly, CD/LP-miCDDP significantly prolonged the blood circulation of encapsulated drug in rats with AUC (o-t) of CD/LP-miCDDP showed a 6.9 fold higher value than that of free CDDP. Similarly, CD/LP-miCDDP showed an eightfold decrease in the clearance (CL) and 3.6-fold higher t 1/2 compared to that of free CDDP. Overall, results demonstrated that targeted and synergistic co-delivery of therapeutic components could be promising in cervical cancer therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

CD59 receptor targeted delivery of miRNA-1284 and cisplatin-loaded liposomes for effective therapeutic efficacy against cervical cancer cells

Wang

Liang

2020

AMB Expr

View full text Add to dashboard Cite

show abstract

“…Furthermore, surface charge properties of NPs are another factor that positively charged NPs are more likely to be uptake by cells than negatively charged ones, while negatively charged NPs have better stealth effect. As previously reviewed, positively charged NPs have shown potential efficacy against pancreatic cancer metastasis and have a better ability to load nucleic acid drugs [ 73 , 110 ]. In addition, the EPR effect is not nearly as significant in human tumors as it is in animal models [ 111 ], and no biomarkers specific for pancreatic cancer, which makes it hard to design advanced receptors and ligands for NPs in TME.…”

Section: Challenges and Potential Problemsmentioning

confidence: 99%

Nanoparticle-based delivery systems modulate the tumor microenvironment in pancreatic cancer for enhanced therapy

Jia

Zhang

et al. 2021

J Nanobiotechnol

View full text Add to dashboard Cite

Pancreatic cancer is one of the most lethal malignant tumors with a low survival rate, partly because the tumor microenvironment (TME), which consists of extracellular matrix (ECM), cancer-associated fibroblasts (CAFs), immune cells, and vascular systems, prevents effective drug delivery and chemoradiotherapy. Thus, modulating the microenvironment of pancreatic cancer is considered a promising therapeutic approach. Since nanoparticles are one of the most effective cancer treatment strategies, several nano-delivery platforms have been developed to regulate the TME and enhance treatment. Here, we summarize the latest advances in nano-delivery systems that alter the TME in pancreatic cancer by depleting ECM, inhibiting CAFs, reversing immunosuppression, promoting angiogenesis, or improving the hypoxic environment. We also discuss promising new targets for such systems. This review is expected to improve our understanding of how to modulate the pancreatic cancer microenvironment and guide the development of new therapies. Graphical Abstract

show abstract

“…The nanocarriers are demonstrated to enhance the therapeutic efficacy, reduce the unwanted adverse effects, improve the blood circulation, and improve the cellular accumulation in the tumor tissues [14,15]. To be specific, liposome has emerged as a one of the most tested carrier system in clinical trials [16]. The unique structure of liposome provides high drug loading, surface modifications, plasma stability and tunable particle size.…”

Section: Introductionmentioning

confidence: 99%

“…The unique structure of liposome provides high drug loading, surface modifications, plasma stability and tunable particle size. Although, liposome accumulates in the tumor tissue via enhanced permeation and retention (EPR) effect, targeted carrier remarkably increase the effectiveness of the therapy [16]. Tumor targeted carrier system selectively accumulate in the tumor and kill the cancer cells without causing unwanted side effects.…”

Section: Introductionmentioning

confidence: 99%

CD59 receptor targeted delivery of miRNA-1284 and Cisplatin-loaded liposomes for effective therapeutic efficacy against cervical cancers

Wang

Liang

2019

Preprint

View full text Add to dashboard Cite

Background: In this study, we have designed the CD59sp-conjugated miRNA-1284/cisplatin(CDDP)-loaded liposomes for the enhanced therapeutic effect against cervical cancers. Methods: A substantially higher uptake of CD59 antibody-conjugated miRNA-1284/CDDP-loaded liposomes (CD/LP-miCDDP) was attributed to the CD59-based receptor-mediated cellular internalization in HeLa cells. Results: MiR-1284 showed a typical concentration-dependent cell killing effect in the cervical cancer cells owing to the downregulation of HMGB1. CD59-antibody conjugated formulation exhibited a significantly lower cell viability compared to that of free CDDP and non-targeted LP-miCDDP. The combination of miR-1284 and CDDP could result in a synergistic anticancer effect on the cervical cancer cells. The IC50 value of CDDP, LP-miCDDP and CD/LP-miCDDP was observed to be 12.4 µg/ml, 7.23 µg/ml and 3.12 µg/ml, respectively. CD/LP-miCDDP exhibited remarkable cell/nuclei rupturing and apoptotic bodies’ formation indicating a severe apoptosis effect in HeLa cancer cells. Flow cytometer analysis showed that CD/LP-miCDDP resulted in maximum apoptosis effect (~60%) compared to CDDP (~20%) or miR-1284 (~12%) treated cells indicating the superior anticancer effect in the cancer cells. Conclusions: Finally, CD/LP-miCDDP significantly prolonged the blood circulation of encapsulated drug in rats with significantly higher AUC (o-t) , t 1/2 and lower CL compared to that of free CDDP. Overall, CD/LP-miCDDP could hold a promising potential in the treatment of cervical cancers.

show abstract

Therapeutic effects and anti-metastasis effects of cationic liposomes against pancreatic cancer metastasis in vitro and in vivo

Cited by 8 publications

References 18 publications

CD59 receptor targeted delivery of miRNA-1284 and cisplatin-loaded liposomes for effective therapeutic efficacy against cervical cancer cells

CD59 receptor targeted delivery of miRNA-1284 and cisplatin-loaded liposomes for effective therapeutic efficacy against cervical cancer cells

Nanoparticle-based delivery systems modulate the tumor microenvironment in pancreatic cancer for enhanced therapy

CD59 receptor targeted delivery of miRNA-1284 and Cisplatin-loaded liposomes for effective therapeutic efficacy against cervical cancers

Contact Info

Product

Resources

About